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B48, APOB: apolipoprotein B48 IDL-C: Intermediate Density Lipoprotein-
Cholesterol 
LPL: lipoprotein lipase 
B100, APOB: apolipoprotein B100 VLDL-C: Very Low Density Lipoprotein-
Cholesterol 
HL, LIPC: hepatic lipase 
A1, APOA1: apolipoprotein A1 LDL-C: Low Density Lipoprotein-
Cholesterol 
FA: fatty acids 
A4, APOA4: apolipoprotein A4 HDL: High Density Lipoprotein SFA: saturated fatty acids 
E, APOE: apolipoprotein E TAGs: Tryacylglycerides PUFA: polyunsaturated fatty acids 
CM: chylomicrons LDLR: Low Density Lipoprotein receptor MUFA: monounsaturated fatty acids 
rCM: remnant chylomicrons LDL-ox: oxidated Low Density Lipoprotein CHO: Carbohidrates 
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Figure 2. Polymorphisms associated with cardiovascular risk (CV 
risk) described in lipoprotein metabolism genes. CV risk vary 
depending on diet interventions.  
 
          Variants conferring more CV risk: 
APOE: -219G/T, ε2/ε2 and ε4/ε4 
APOA4: Thr347Ser 
APOB: -516C/T and Gly4154Leu + Ala3611Gly 
 
          Variants conferring less CV risk: 
APOA1: -75G/A 
APOA4: Thr347Ser and Gln360His 
APOA1 and APOA4 (combined): -75G/A and Thr347Ser,respectively 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Lipoprotein metabolism pathway. In orange, 
apolipoproteins whose genetic variations has been described. 
HL variations also described. 
Enterocytes get dietary fat, then cholesterol is transported to 
the liver by chylomicrons and to peripheral tissues by LDL 
particles. Cholesterol reverse transport allow its elimination by 
the liver through the HDL particles. 
CONCLUSIONS 
 
APOE, APOA1, APOA4 and APOB genes showed responses to different diet 
interventions, but LIPC gene did not. 
 
There are evidences associating polymorphisms with diet compounds, which is 
traduced in changes in lipid metabolism, but it is needed more information to 
consider nutrigenomics for the clinical practise. Genomic studies have to be 
performed, but also it is important not to set aside other factors, to determine CV 
risk and set a personalized medicine in each case, focusing  specially in genetic 
individual variations. 
 
It is still far reducing CV risk and, as a consequence, the morbidity and mortality 
of CVD, applying nutrigenomics. However, the knowledge of variants and 
interactions will allow to treat patients, reducing their risk factors by performing 
different diet interventions depending on the genotype. 
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 INTRODUCTION 
 
Cardiovascular risk (CV risk) is determined by genetic and 
acquired factors. They both involve hypertension, dyslipemia 
and diabetes, key factors to develop cardiovascular diseases 
(CVD). In addition to other risk factors, lipoprotein levels are 
used to determine  the CV risk on an individual. 
However, it exists variability between individuals with the 
same profile. This can be explained by genetic variations that 
modify CV risk. 
Diet is an environmental factor that involve individual 
variation. Different studies have been performed to analyse 
individual response to different diet interventions, depending 
on the genotype. This review collects the most relevant 
information about APOE, APOA, APOB and LIPC genes 
involving lipoprotein level variations. 
STATE OF THE ART 
 
In the last two decades, it has been described the role of diet in individual 
variations, depending on the genetic profile. However, to consolidate this 
information, it is necessary to replicate these studies with more patients. This will 
clarify some contradictory results produced for the low number of subjects with 
uncommon variations. Currently, the knowledge is lack of soundness. 
 
Expected short term goals: 
 
To discriminate those SNPs that drive to functional protein alterations in order to 
reduce wrong associations. 
 
To predict interactions: several genes interacting with several diet compounds 
lead to different phenotypes. Use of transcriptomics, proteomics and 
metabolomics to progress in the field of nutrigenomics. 
 
To standardize study designs to make data collection easier, classifying the 
subjects depending on their characteristics. 
 
To create consortiums to increase the number of subjects 
GOALS 
 
• To analyze the connection between polymorphisms in 
genes involved in lipoprotein metabolism and CV risk. 
 
• To evaluate the implication of nutrigenomics in the 
prevention or treatment of CVD in high risk individuals.  
METHODS 
 
The search of the bibliography has been performed in the 
data base Medline using the key words: polymorphisms, 
lipoproteins and cardiovascular biomarkers. Among the 28 
papers found, 12 has been used. 
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